Peer-reviewed veterinary case report
Outcome of surgery and lomustine for certain grade II mast cell
By Néčová, S et al.·Published in Australian veterinary journal·2021·Small Animal Oncology, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine.
- Species:
- dog
Plain-English summary
A group of 21 dogs with grade II mast cell tumors (a type of skin cancer) underwent surgery and received a chemotherapy drug called lomustine. None of the dogs had their tumors come back locally after treatment, although three developed metastatic disease (cancer spread to other parts of the body). The dogs showed a strong survival rate, with 95.2% alive one year after treatment and 90.5% after two years. This approach resulted in better outcomes compared to similar cases without chemotherapy, suggesting that lomustine can be beneficial for dogs with this type of tumor.
People also search for: dog mast cell tumor treatment · lomustine for dogs · dog cancer survival rates · mast cell tumor surgery outcome · grade II mast cell tumor in dogs
Abstract
OBJECTIVES: The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. ANIMALS: Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. PROCEDURES: Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re-staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease-free interval (DFI) and median survival time (MST) were calculated using Kaplan-Meier method. RESULTS: Twenty-one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow-up period of the whole study population was 1112 days (358-2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One-year and 2-year survivals were 95.2% and 90.5%, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33565080/